- 中文名
- ((S)-2,2-二氟环丙基)(3-(2-((1甲基-1H-吡唑-4-基)氨基)嘧啶-4-基)-3,8-二氮杂双环[3.2.1]辛烷-8-基)甲酮
- 英文名
- ((S)-2,2-Difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone
- CAS号
- 1883299-62-4
- 分子式
- C18H21F2N7O
- 分子量
- 389.4
- 中文别名
- Brepocitinib
- 英文别名
- Brepocitinib; PF-06700841; 3X8387Q25N; PF06700841; [(1S)-2,2-difluorocyclopropyl]-[(1S,5R)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone; Methanone, ((1S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-4-pyrimidinyl)-3,8-diazabicyclo(3.2.1)oct-8-yl)-; ((1S)-2,2-difluorocyclopropyl)-((1S,5R)-3-(2-((1-methylpyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo(3.2.1)octan-8-yl)methanone; RefChem:121326; PF-841; TYK2/JAK1 Inhibitor PF-06700841; PF 06700841; 4-((1R,5S)-8-((1S)-2,2-difluorocyclopropanecarbonyl)-3,8-diazabicyclo(3.2.1)octan-3-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine; PF-06700841 free base; Brepocitinib [USAN]; [(1S)-2,2-difluorocyclopropyl]-[(1R,5S)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone; Brepocitinib (USAN); [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone; G4J; BREPOCITINIB [INN]; BREPOCITINIB [WHO-DD]; CHEMBL4297477; SCHEMBL17512502; UNII-3X8387Q25N; US9663526, Example 7; GTPL10459; BUWBRTXGQRBBHG-MJBXVCDLSA-N; BDBM329924; DTXSID801091591; EBC-00709; WHO 11169; DB15003; Brepocitinib, PF-06700841 free base; compound 23 [PMID: 30113844]; NCGC00510805-01; DA-56738; D11537; (1S)-2,2-DIFLUOROCYCLOPROPYL)(3-(2-((1-METHYL-1H-PYRAZOL-4-YL)AMINO)PYRIMIDIN-4-YL)-3,8-DIAZABICYCLO(3.2.1)OCTAN-8-YL)METHANONE
